Can a Triple-Drug combo tame an aggressive lymphoma without harsh chemo?
NCT ID NCT04004572
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of three drugs—sintilimab, pegaspargase, and anlotinib—can effectively treat stage IV extranodal NK/T-cell lymphoma in patients who are not healthy enough for high-intensity chemotherapy. The study enrolls adults with newly diagnosed or relapsed disease and evaluates how many achieve a complete response after 24 weeks of treatment. The goal is to find a safer, yet effective, alternative for this challenging condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of three drugs: sintilimab (an immunotherapy), pegaspargase (a chemotherapy agent), and anlotinib (a targeted therapy)
- What this could lead to
- If successful, this combination could offer a gentler, effective treatment option for people with advanced NK/T-cell lymphoma who cannot tolerate standard high-intensity chemotherapy.
- What could go wrong
- This is a small, early-phase trial, so results may not hold up in larger studies. The drug combination may cause side effects, and not all patients may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER/T-CELL LYMPHOMA, NASAL AND NASAL-TYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xinhua Hospital
Shanghai, Shanghai Municipality, 200092, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.